V V V V V V V V V V V V V Ve e e e e e e e e e e e e e e e e er r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r rt t t t t t t t t t t te e e e e e e ex x x x x x x x x x x p p p p p p p p p p pr r r r r r r r r re e e e e e e e es s s s s s s s s s s s se e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e en n n n n n n n n n n n n n n n n n n n n n n n n n n n nt t t t t t t t t t t t t t t ta a a a a a a a a a a a a a a F F F F F F F F F F Fu u u u u u u u ul l l l ll l l l l c c c c c c c c c c c c c c c c c c c c c c ce e e e e e e e e e e e e e e e e e e e e e e er r r r r r r a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a al 
ContemporaryOBGYN.net 9.01% IN 1992 
O P E R A T I V E V A G I N A L D E L I V E R I E S

3.30%
IN 2013 a a a a a a a a a a a a a a a a a a a a a a a a a at t t
t t t t t t t t t t t t t t t t t t t t t t t t t t t t t t ti i i i i i i i i i i i i i i i i i i i i i a a a a a a a a a a a a a a a a at t t t t t t t t t t t t t t ti i i i i i i i i i i i i i i i i io o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o o s s s s s s s s s s s s s s s s s s st t t t t t t t t t t ta a a a a a a a a a a a a a a a a a a at t t t t t t t t t t t t t t t t t t t t t t o o o o o o o o o o o o o
o o o o on n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n p p p p p p p p p p p p p p p p p p p p p pt t t t t t t t tu u u u u u u u u u u u u ur r r r r r r r r r re e e e e e e e e e e e e ed d d
e e e e e e e e e e e e e e e e e > > > > > > > > > > > > > 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w w we e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e ee e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e ek k k k 
t t t t t t ti i i i i i i i i i i i i i i i i i i i i i i i i i i i io o o o o o o o o o o o o o o o o o o o o o o o o o o o o o on
n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n 3 CM
CM
Th e decision whether to remove the Essure device should be made after detailed examination and careful planning with the patient.
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o o on n n n n n n n n n n n n n n n n n n n n n n p p p p p p pt t t t t t t t t t t t tu u u u u u u u u u ur r r r r r r r r r r r r r r re e e e e e e e e e e ed d w w w w w w w w w w w w w w we e e e e e e e e e ee e e e e e e e e e e e e e e e ek k k k k k k k k k k k k k k k k k k k k k k k k ks s s s s s s s s s s s s s s s s s s s s n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n I n my prior editorial on this topic, I reviewed the principal reasons why prescription medications in this country are so costly. I pointed out that the "market" in prescription drugs is grossly distorted by opaque pricing, costly intermediaries, price inelasticity and a lack of consumer control as well as manufacturer rebates, direct-to-consumer advertising and co-pay coupons. I also noted that brand drug makers are free to set their own prices, which in the case of specialty drugs can be astronomical (e.g., spending on just Humira exceeded $10 billion in 2015). 1 To make matters worse, when patents expire, manufacturers can delay conversion of their costly brand drugs to less expensive generics through "product hopping" and "ever-greening. " But even after generic transitions occur, limited competition frequently permits generic manufacturers to achieve eff ective monopolies, sustaining high prices. Well-intentioned government regulations (e.g., Orphan Drug Act) designed to promote innovation have had disastrous unintended consequences for drug prices. Medicare's inability to negotiate drug prices or import inexpensive foreign drugs also drive up costs. And then there are the fi nancial incentives that drug companies dangle in front of physicians to prescribe high-cost medications. While the sheer complexity of the problem is daunting, there are simple steps that the Federal government could take to restrain prescription drug costs without restraining the extraordinary innovation that is the hallmark of the US pharmaceutical industry (Table 1) .
Increase drug pricing transparency
Many stakeholders from the National Academy of Medicine (NAM) to the Trump Administration have advocated for greater transparency in the various fi nancial fl ows and profi t margins within the drug supply chain (e.g., manufacturers, pharmacy benefi t managers [PBMs] , and retail, wholesale and 340 B-eligible hospital pharmacies). 2, 3 For example, a patient goes to her pharmacy to pick up a prescription drug and, if the drug is covered by an insurer, likely has a co-pay. Subsequently the manufacturer sends a rebate to the PBM hired by the patient's insurer to negotiate prices. Th e PBM, after retaining some of the rebate, passes the remainder on to the insurer, which often uses it to off set premium costs to retain customers. Th is incentivizes higher drug costs since patients will potentially pay exorbitant sums for a drug their physician says they need but manufacturers' rebates go to intermediaries and not to the In the second part of this series, potential solutions to ⇒ x the rising drug cost problem are examined.
In the ⇒ rst part of this series, Dr. Lockwood examined the challenges posed by the high cost of brand-name drugs and why prescription medications are so expensive in Amerca. Government regulations, suppression of generic competition, and direct payment to physicians all play a large role. Read Part 1 from last month's issue: Requiring drug makers to publish their prices and rebates would expose the true costs of intermediaries and likely exert downward pressure on pricing due to improved market effi ciency. Th e NAM has proposed that the Department of Health and Human Services (HHS) obtain, curate, and publicly report drug pricing data (e.g., list prices, rebates, discounts, net prices) on a quarterly basis, conduct analyses of these data, and inform the Food and Drug Administration (FDA) and Federal Trade Commission (FTC) of possible abuses. 2 Beyond the "dog shaming" impact of such reporting on drug pricing, this would likely fuel meaningful antitrust actions to enhance market effi ciency.
In a more radical disintermediation step, this January, HHS proposed modifying Medicare Part D rules to require manufacturers to pass discounts directly to Medicare patients at the pharmacy counter rather than indirectly, through rebates to intermediaries like PBMs. 4 Currently Medicare patients are not eligible for manufacturers' patient assistance plans because of federal kick-back restrictions but perversely, rebates to intermediaries are allowed. While this proposal holds great promise for reducing individual patient drug costs and seems inherently more just, it does risk increasing Part D premiums and reducing pressure to switch to generic or biosimilar specialty drugs. 4 Similarly, Congress should eliminate the Medicaid drug rebate program, which discourages drug
Increase drug pricing transparency Reform Federal regulations that are driving up drug prices Allow select drug importation
Control unscrupulous manufacturing practices
Institute value-based payment for medications TABLE 1 Steps to ensure that medications are more affordable without sti⇓ ing innovation in the US pharmaceutical industry.
• Encourage the Trump Administration to continue to accelerate generic drug approval and strengthen generic drug competition.
• Reform the Orphan Drug act so that it cannot be extended to widely sold generic drugs and is triggered by a lower number of affected patients (e.g., 30,000 vs. 200,000).
• End the 2006 FDA Unapproved Drug Initiative, which has made long-used, safe, inexpensive agents expensive and in short supply.
• Require the FDA to permit reduced-dose medication vial sizes, encourage multi-dose vial use, and extend shelf lives of medications to decrease wastage.
• Enact Tort reform so that drug companies are liable only for known or predictable harms not disclosed during an FDA review, and not for rare, unpredictable harms.
• When market distortions exist leading to drug shortages or high prices, the FDA should use its authority to support importation
• Congress should eliminate the tax deductibility of direct-toconsumer (DTC) advertising.
• A strict industry code of conduct should be adopted for such DTC marketing.
• Congress should require mandatory disclosure of industry support of not-for-pro⇒ t patient advocacy groups subsidized by drug makers to promote their products.
• State and federal governments should tighten restrictions on drug detailing visits and inducements to MDs.
• Brand drugs should be priced based on value (outcome over cost). Outcome should include effects of a drug on survival, function, and quality of life years added. Cost estimates should consider a drug's net impact on reducing other health costs (e.g., hospitalization, surgery, need for multiple medications, rehabilitation, nursing home care)
• Department of Health and Human Services (HHS) should obtain, curate and publicly report data on drug pricing.
• HHS should require manufacturers to pass discounts directly to Medicare patients rather than offer rebates to intermediaries like Pharmacy Bene⇒ t Managers and insurers.
• Congress should eliminate the Medicaid drug rebate program, which discourages drug makers from discounting drug costs to any payer.
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makers from discounting drug costs to any payer since it would increase the cost of their rebate to Medicaid.
Reform Federal regulations that are driving up drug prices
Th e Trump administration has accelerated FDA approval of generic drugs with over 1000 new approvals in 2017 potentially saving $9 billion. 3 Moreover, it is seeking to close loopholes used by brand drug makers to restrain generic competition. More importantly, HHS is seeking authority to increase Medicare's ability to negotiate drug prices. Th ese actions deserve robust bipartisan support. I believe strongly that there is an urgent need to apply the full weight of US government drug purchasing power to negotiate drug prices for both Medicare and Medicaid and create a national formulary like those used by most other industrialized nations.
Th ere is need to reform the Orphan Drug Act of 1983. 2 First, fi nancial incentives for prevention and treatment of rare diseases should not be extended to widely sold generic drugs (e.g., 17-hydroxyprogesterone caproate). Second, reducing the patient number threshold defi ning an "orphan" disease from less than 200,000 to a more reasonable number (e.g., 30,000) would have an immediate benefi cial eff ect on costs. I would also advocate ending the 2006 FDA Unapproved Drug Initiative, which was designed to bring grandfathered medications under stricter control but has resulted in substantially higher prices, on average 37% higher, and frequent drug shortages.
5
Other simple regulatory actions with potentially major economic benefi ts include having the FDA permit reduced-dose medication vial size, encourage utilization of multiuse vials, and signifi cantly extend the recommended shelf lives of medications to decrease wastage. Th e latter is particularly egregious as the designated shelf life of drugs is often not evidence-based and frequently grossly underestimated. 6 Finally, we need Tort reform. Drug companies should be liable only for known or predictable harms purposefully not disclosed during an FDA review, and not for rare harms undetectable during Phase 1 to 3 clinical trials. Reducing such liability costs could have a demonstrable effect on drug pricing.
2
Allow select drug importation
Because foreign governments eff ectively negotiate with US drug makers for lower prices and many of the components of U.S. medications are manufactured abroad, there is an inherent logic to allowing drug importation. Th e FDA has pointed out drugs manufactured in a foreign country for the US market are produced in FDA-registered plants that also make drugs sold (at far lower prices) in other countries, an implicit indicator of drug safety. 7 However, there are risks to unrestrained importation. A substantial number of drugs imported via the Internet have been reported to be less eff ective or ineff ective and/or to contain impurities or toxins. 8 Th us, FDA oversight would be needed for any such program, which would add costs. Califf and Slavitt have argued that when market distortions exist leading to drug shortages or high prices, the FDA should use its authority to support importation. 9 Th is seems like a very reasonable middle ground.
Control unscrupulous manufacturing practices
Th ere is no doubt that directto-consumer (DTC) advertising works or we would not be fl ooded with the vast number of ads we see on television touting high-cost specialty drugs that clear skin, prevent clots, or permit quicker recovery from chemotherapy. Most come with the off er of a manufacturers' patient assistance plan or co-pay coupons (if commercially insured) which reduces patient out-of-pocket expenses for costly brand drugs but also reduces use of inexpensive generic drugs by 60%. 2 While First Amendment protections likely make it impossible to ban such advertising, Congress should eliminate the tax deductibility of DTC advertising and an industry code of conduct should be adopted for such marketing. Similarly, Congress should require mandatory disclosure of industry support for not-for-profi t patient advocacy groups, which are often heavily subsidized by drug makers to promote their products. 2 Finally, it should tighten restrictions on drug detailing visits and inducements to MDs.
Institute value-based payment for medications
Health care fi nancing is evolving from a fee-for-service system that incents Congress should eliminate the tax deductibility of DTC advertising and an industry code of conduct should be adopted.
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volume to a value-based payment (VBP) system that rewards better outcome for lower costs. Prescription drug pricing should also be based on a VBP paradigm.
9 Pricing of brand medications should consider the high development costs and substantial fi nancial risks manufacturers incur to bring new drugs to market (e.g., 90% of new drugs fail to reach market approval). Indeed, patent protections permit exclusivity to sell novel drugs as a hedge against such development risks, but such exclusivity should not be a license for unrestrained pricing. Rather, brand drug pricing should also be based on value-eff ects of a drug on actual outcomes (e.g., survival, improved function, and quality of life years added) over cost. A drug's impact on aggregate health costs (e.g., need for hospitalizations, surgery, multiple medications, rehabilitation, and nursing home care) should also be considered in price determinations. While these measurements are complex and require time to calculate, the 21 st Century Cures Act of 2016 should help fund federal agencies that can make such calculations. In the end, VBP for drugs is likely the most eff ective way of restraining medication costs without restraining innovation.
Take-home message
America should be justifi ably proud of the incredible discoveries and innovative therapies that its pharmaceutical industry has produced, often in concert with medical school researchers. However, prescription drug costs in this country are far too high and rising at many multiples of the rate of infl ation. Th ese costs threaten the fi nancial viability of Medicare, Medicaid and indeed, our entire health system. Our system also burdens American families with high out-of-pocket costs. Th ere are many causes of this crisis, including an opaque and distorted pharmaceutical market, perverse government regulations, unscrupulous marketing techniques, and a failure to leverage the federal government's vast negotiating leverage. Fortunately, there are some very straightforward steps that can be taken to lower costs without impeding innovation. Th ese include measures to increase price transparency to restore market forces, reform of well-meaning Federal regulations whose unintended consequences are paradoxically infl ating drug prices, eliminating or at least restraining unscrupulous marketing practices, and ultimately transitioning to a VBP system for medications. 
TO THIS YEAR'S INTERNS AND RESIDENTS…
WELCOME TO CONTEMPORARY OB/GYN
As you begin your new year in women's health we invite you to make Contemporary OB/GYN part of your regular reading. Taken from the pages of the Contemporary OB/GYN magazine, the newsletters offer ob/gyns at all stages of their careers:
JULY 2019
CONTEMPORARY OB/GYN 7 PEER-REVIEWED O perative vaginal delivery is an important management option for patients in the second stage of labor whose clinical situation requires expedited delivery. There has been a decreasing trend of using either vacuum or forceps during delivery, which coincides with the increasing rates of cesarean delivery during the past 3 decades. 1 Operative vaginal delivery decreases maternal risk of infection and hemorrhage, shortens maternal recovery and length of hospitalization postpartum 2 and preserves a woman's reproductive options by eliminating risks of both vaginal birth after cesarean delivery (VBAC) and abnormal placentation in future pregnancies but operative vaginal delivery also involves risks for both neonatal and maternal complications which includes a two-to six-fold increase in third-and fourth-degree perineal tears depending on the type of operative vaginal delivery. 3 Th e desire to minimize pelvic fl oor trauma during delivery has resulted in a shift in recent obstetric practice away from use of forceps toward vacuumassisted vaginal delivery, possibly due to the purported higher rates of obstetric anal sphincter and pelvic fl oor injury associated with forceps-assisted delivery (8%-23%), compared to vacuumassisted delivery (6%-9%). 4 The decrease in operative delivery rates seen in conjunction with the continued increase in cesarean delivery rates is not likely to reverse unless there is a concerted eff ort to teach vacuum extraction to residents in training. In addition, many ob/gyns are reluctant to use vacuum extraction because of concerns about anal sphincter and pelvic fl oor injuries and neonatal complications with their associated risk of litigation. 3, 5 History Th e history of using vacuum to aid vaginal delivery has been described in multiple texts, most notably by J.A. Chalmers in his book "Th e Ventouse" published in 1971.
6 By most accounts, the technique was fi rst attempted unsuccessfully by Dr. James Yonge in 1706. 7 Rising cesarean delivery rates along with inadequate training has largely sidelined vacuum deliveries, even though the procedure has its bene⇒ ts. 
VACUUM DELIVERY
counts could be the fi rst time that a device similar to the modern vacuum was used successfully but it unfortunately failed to gain favor with the medical community. 8 More than a century later, a Swedish professor, Tage Malmstrom, developed the Malmstrom extractor and published a series of studies. 9 Th is led to more widespread adoption of the vacuum extractor to aid childbirth. Its adoption in Northern European countries increased in 1970 followed by adoption in the United States.
Indications and contraindications
Th e fi rst American College of Obstetricians and Gynecologists (ACOG) document on operative vaginal delivery was published in 1991. Th e document, previously called the Technical Bulletin, has undergone multiple revisions and replacements and was fi nally replaced by Practice Bulletin Number 154, published in November 2015 and reaffi rmed in 2018. 10 Since then, indications and contraindications for vacuum delivery have been enumerated in several publications. Th ey are summarized here in Tables 1 and 2. 10-13 Table 3 off ers tips for ensuring a successful vacuum delivery. Of note, none of these indications is absolute and a cesarean delivery can be off ered in all these circumstances.
There is no consensus regarding what is considered adequate analgesia for vacuum delivery. Epidural anesthesia is preferable but absence of an epidural is not a contraindication for vacuum delivery.
Controversies
Vacuum vs forceps
One advantage of forceps over vacuum extraction is its higher success rate in achieving a vaginal birth. 16 However, forceps deliveries are more likely to result in neonatal facial laceration, instrument marks and bruising, facial nerve palsy, corneal abrasions and external ocular trauma, skull fracture, and intracranial hemorrhage 5,10, Maternal complications associated with forceps deliveries include major perineal and vaginal tears, third-and fourth-degree perineal lacerations associated long term with pelvic organ prolapse. 8, 14, 15 Conversely, vacuum extraction can result in fetal scalp laceration, cephalohematoma formation, and subgaleal or intracranial hemorrhage (Table 4) . 10 Retinal hemorrhages and increased rates of hyperbilirubinemia have also been reported. In contrast, a recent retrospective cohort study that included all singleton, term, cephalic vaginal deliveries in Kaiser Permanente Northern California between 2013 and 2014 found that women with vacuum-assisted vaginal deliveries had four times the odds of obstetric anal sphincter injury (OR 4.23,95% CI 3.59-4.98) compared to those who did not. In this study, the predominant choice of instrument for operative vaginal delivery was vacuum extraction at 6.2% compared to forceps, which was only 0.4%. Hence, the authors eliminated forceps deliveries from the study. Th e primary outcome studied was third-or fourth-degree perineal lacerations. Th is group also noted that women whose secondstage labor lasted 180 minutes vs less than 60 minutes had three times the odds of obstetric anal sphincter injury (OR 3.20, 95% CI 2.62-3.89).
5
Pelvic ⇓ oor disorders
Nygaard et al 20 found that approximately 25% of women in the United States had at least one pelvic fl oor disorder, with the rate almost double in women older than age 80. 20 Because the US population aged 65 and older is expected to double between 2010 and 2050, 21 this statistic underscores the potential cost to the health care system and the likelihood that a signifi cant part of the population will suff er from such a condition, which will seriously impact quality of life. Blomquist et al followed women annually from their fi rst delivery for up to 9 years looking for evidence of pelvic fl oor disorders. 20 Th ey found that cumulative incidence of each pelvic fl oor disorder was signifi cantly associated with mode of delivery. Compared with spontaneous vaginal delivery, cesarean delivery was associated with a signifi cantly lower hazard of SUI, overactive bladder (OAB), and pelvic organ prolapse (POP). Indeed, vaginal delivery is associated with an almost two-fold increase in risk of developing SUI, compared with cesarean delivery, with a smaller eff ect on urgency urinary incontinence (UUI). 22 In contrast, operative vaginal delivery was significantly associated with a higher hazard of anal incontinence and POP. Th ere is evidence that 10% to 20% of vaginal deliveries result in levator ani damage that is undetected at the time of delivery, 23 the eff ect of which evolves over decades, resulting in a long latency Ramm et al. found that nearly onefourth (24%) of the women in their study who had undergone a vacuumassisted delivery incurred obstetric anal sphincter injury (OASIS).
5 Th at is a substantial increase over historically quoted 6% to 9% OASIS rates with vacuum-assisted vaginal delivery and at least equal to the 8% to 23% rates quoted with forceps-assisted vaginal deliveries. 5, 25 Th is raises the question of whether the rate of maternal complications is as low with this procedure as previously believed. However, these investigators also noted that duration of second-stage labor was independently associated with obstetric anal sphincter injury, even after controlling for vacuum-assisted vaginal delivery and VBAC.
5 Because a longer second stage has become the norm in an effort by the obstetrical community to prevent primary cesarean deliveries, we may fi nd that it has become a risk factor for OASIS.
26
Adequacy of resident training
As long ago as 1996, when operative vaginal deliveries were much more common, a study that surveyed a random sample of 1600 trainees in the United States about their experience of operative vaginal delivery training established that 25% of trainees with < 10 years of experience had not received training on vacuum extraction during their residency. Despite this, 88% of the same group carried out the procedure regularly. 27 Given current use of this modality, we can only surmise how much less experience a recent graduate can be expected to have today, and how much less skill at performing an operative vaginal delivery would be anticipated, possibly resulting in worse maternal and neonatal outcomes than have been reported in the past.
Th e impact of changes in work hours, attending presence, and involvement in deliveries, and simulation training for these relatively rare obstetrical procedures is unknown. A 2017 survey of Irish and Canadian trainees demonstrated that trainee comfort levels with operative vaginal delivery are positively correlated with numbers performed.
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Th is did not hold true with trainee selfconfi dence, suggesting that other factors are involved. (Trainee confi dence was assessed based upon their last few forceps deliveries using a modifi ed version of a six-item fi ve-point tool (maximum score out of 30) previously validated for gynecology trainees to measure self-confi dence. Measures of trainee comfort were assessed across 13 variables of second-stage assessment, measured on a 5-point Likert scale ( Because the United States has one of the lowest rates of operative vaginal deliveries of all developed countries, 1, 30 many training programs are developing simulation training as part of their core curriculum to teach residents operative delivery skills. Th ere is some evidence to suggest that local "in-house" simulation training is the most eff ective.
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Episiotomy with vacuum extraction?
None of the accepted national guidelines, including those from ACOG, the Council of the Society of Obstetricians and Gynaecologists of Canada (SOGC), and the UK's Royal College of Obstetricians and Gynaecologists (RCOG), have included episiotomy as a mandatory step in vacuum delivery. Rather, the guidelines recommend restrictive use of episiotomy, using the operator's individual judgement. 8, 32, 33 Unfortunately, indications for this selective procedure are not clearly defi ned. Numerous studies have noted that episiotomy use is related to increased rates of several obstetric complications, including urinary and anal incontinence, postpartum hemorrhage, and pain. 10 Th is procedure can also be related to a higher, rather than lower, incidence of advanced perineal tears. 34 A meta-analysis of episiotomy in vacuum delivery performed by Sagi-Dain and Sagi in 2015 concluded that median episiotomy was related to a higher risk of OASIS in vacuum delivery in nulliparous women (OR 5.11, 95% CI 3.23-8.08) as well as parous women (OR 89.4, 95% CI 11.8-677.1).
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Their findings suggest that midline and mediolateral episiotomy in parous women may increase risk of advanced perineal tears at vacuum delivery, but that lateral episiotomy in nulliparous women appears to be associated with a decreased risk of OASIS. Mediolateral episiotomy may increase risk of postpartum hemorrhage and pain.
Vacuum extraction in LBW neonates
Th at the patient should be over 34 weeks and the estimated fetal weight should be over 2500 g for vacuum extraction is generally accepted. 10 However, in the mid-1990s, both Morales et al and Th omas and associates showed no signifi cant diff erences in neonatal outcomes in vacuum extractions among preterm infants with weights below 2500 g and 2000 g, respectively. 35, 36 In 2017, Aviram et al. again studied this group of neonates and found no increase in birth injury in neonates. 
Long-term neonatal complications
Known complications of operative vaginal deliveries may be related to the complicated labor, rather than the procedure used to eff ect the delivery. Fetal size greater than 4000 g can play a part, 38 as can a prolonged second stage.
5
Operative vaginal delivery was associated with a rate of neonatal encephalopathy of 4.2 per 1000 term neonates compared with 3.9 per 1000 delivered by cesarean section. 39 Another study that compared vacuum extractions, cesarean deliveries and spontaneous vaginal deliveries showed that the rate of intracranial hemorrhages (both traumatic and non-traumatic) was more than six times greater among newborns delivered by vacuum extractions (19.0 per 10,000) and more than double that for those born by cesarean (7.3 per 10,000) compared with infants born by spontaneous vaginal delivery (2.8 per 10,000). Even after adjusting for indication for operative delivery and other covariates, these newborns had a 10-fold risk for traumatic hemorrhages and more than double the risk for non-traumatic hemorrhages. 40 However, longterm outcomes in children in Sweden 12 CONTEMPORARYOBGYN.NET C hronic pelvic pain is a common chief complaint, accounting for approximately 10% of referrals to a gynecologist, 20% of hysterectomies and 40% of diagnostic laparoscopies.
1 Th e complex and often multifactorial nature of the disorder makes management challenging for patients and providers alike, which can frequently lead to both provider and patient dissatisfaction. 2 Th is straightforward review of the most common etiologies, evaluation, and opioid-sparing management strategies is intended to demystify the disorder and empower providers to improve women's quality of life through practical, evidence-based strategies.
De⇒ ning 'chronic' pelvic pain
Chronic pelvic pain has traditionally been defined as noncyclic pain of 6 months duration that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back or the buttocks, and is of suffi cient severity to cause functional disability or lead to medical care. 3 Th is broadly defi ned anatomic region necessitates an equally broad differential diagnosis, with potential sources of pain not limited to the genitourinary system. Gastrointestinal, neurological, and musculoskeletal sources of pain, with which the general ob/gyn may be less familiar, must also be considered. Adding to this complexity, chronic pain syndromes usually have a central nervous system (CNS) component: input from peripheral sources is more readily passed along through the spinal cord to higher cortical centers, leading to perceived pain that can appear disproportionate to the peripheral stimulus. Th is combination of multiple anatomic structures over which no individual medical specialty has comprehensive knowledge, and alterations in central pain processing belie the need for a multidisciplinary approach.
Neuropsychobiology of chronic pelvic pain
Historically, the severity of chronic pelvic pain was felt to be directly proportional to the extent of pathology. However, studies using diagnostic laparoscopy have shown that the extent of pelvic pain does not correlate well with the extent of endometriosis or adhesions present in the pelvis. 4 Th is observation is consistent with current thinking about chronic pain syndromes in that, unlike acute pain, chronic pain involves both CNS and peripheral nervous system pathways. Alterations in central pathways are highly dependent on psychosocial infl uences, with anxiety and stress suspected to amplify the experience of pain, independent of the In addition, there is a strong association between a history of physical or sexual abuse and development of chronic pelvic pain. Th is relationship could be causal, related to sensitization via alterations in central processing, or coincidental. Regardless of the relationship, concurrent treatment of these psychosocial comorbidities plays a key role in treatment success.
7,8
Establishing a treatment relationship
Given the prevalence of comorbid anxiety, depression, and sexual abuse with chronic pelvic pain, successful treatment relies heavily upon establishing a trusting, therapeutic relationship with these patients. A small qualitative study of the attitudes of patients with chronic pelvic pain toward their care revealed four main themes, which can be reframed as a useful guide for establishing a productive treatment relationship 9 :
1. Provide a sense of personalized care 2. Help the patient to feel understood and taken seriously
Emphasize potential explanation(s)
for the pain, as much as "curing" it
Provide reassurance
Providing a sense of personalized care and helping patients to feel understood and taken seriously often translates to a signifi cant amount of face-to-face time, which can be challenging to accommodate in a busy offi ce practice. However, the additional time spent at the initial visit can often be recouped because future visits are shorter and less frequent. In fact, a patient's favorable impression of the initial visit has been shown to be associated with a higher likelihood of complete resolution of pain.
10 Helping patients suff ering from chronic pain to feel they are being taken seriously requires special attention, as patients are often sensitized to even subtle messages from providers that their pain is "all in their head." It is therefore helpful to provide tangible examples to patients of how both central and peripheral pathways are involved in our pain experience, such as the common experience of noting a laceration only long after the injury may have occurred, or times in which a stubbed toe resulted in a surprisingly intense experience of pain.
Etiologies
As is true with most other conditions, the etiology of chronic pelvic pain can be consistently identifi ed through a detailed history and physical exam, provided the starting point is a reasonable list of potential diagnoses. Th e broad anatomic area that falls under the defi nition of pelvic pain requires an equally broad list of potential conditions, which can often be overwhelming. Th erefore, it may be useful to organize the diff erential diagnosis anatomically into the uterus, cervix, fallopian tubes, ovaries, vagina, bladder, ureters, rectum, intestines, pelvic bones, pelvic musculature, and pelvic nerves. Th e character of a patient's pain may help to further narrow the diff erential diagnosis, given the two different physiologic pathways that can be involved in pelvic pain: visceral and somatic (Table 1) .
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While an exhaustive list of etiologies of pelvic pain is too expansive to fully itemize, 12 only a handful of conditions account for the majority of chronic pelvic pain, with multiple causes often present concurrently (Table 2) .
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For the general ob/gyn, the ability to diagnose and appropriately treat or refer these conditions would make a tremendous impact for most women who suff er from chronic pelvic pain.
Th e aforementioned extended time at the initial visit may best be used to collect a detailed history, going back to our training roots and eliciting the seven dimensions of the symptom (Table 3) and to perform a detailed exam. In addition, it is paramount to ask the patient what she thinks her pain may represent. Patients often fear that their
Visceral pain Somatic pain
Characteristics Poorly localized.
Associated with nausea, vomiting, diaphoresis
Discrete and localized
Structures involved
Sympathetic -ovaries, fundus, upper cervix Parasympathetic -lower cervix, vulva
Pelvic bone, ligaments, muscles and fascia
TABLE 1
Characteristics and structures involved in two physiologic pathways of pelvic pain 11 Additional time spent at the initial visit can often be recouped because future visits are shorter and less frequent.
CHRONIC PELVIC PAIN
pain is due to malignancy or some asyet-undiscovered and potentially lethal condition. Often, these anxieties can be readily assuaged at the initial assessment by taking the time to explain the rationale for the most likely diagnosis. Failure to identify these concerns can signifi cantly impair further treatment. Screening for interstitial cystitis quickly identifi es a subset of patients who suffer from a non-gynecologic condition that frequently presents with chronic pelvic pain. Urinary frequency is often the first symptom. Evaluating for pain that improves with defecation or onset of symptoms associated with changes in frequency or form of stool will screen for irritable bowel syndrome. Evaluation should also include assessment of the patient's psychosocial situation, including sexual function, presence of depression, post-traumatic stress disorder, and any history of physical or sexual abuse. Th e International Pelvic Pain Society (IPPS) has a detailed history and physical examination form available for download in multiple languages (https://www.pelvicpain. org/IPPS/Professional/DocumentsForms/IPPS/Content/Professional/ Documents_and_Forms.aspx).
A careful abdominal exam, which includes light and deep palpation, will identify neuralgias. Single-digit palpation with both fl exion and relaxation of the rectus abdominus muscles will distinguish abdominal wall pathology from intra-abdominal sources: focal pain that worsens with engagement of the abdominal muscles is highly likely to be related to the abdominal wall, whereas pain that improves when the rectus abdominus muscles are fl exed may suggest a visceral source. Evaluation of spinous processes and paraspinal muscle tenderness along with lower extremity strength, sensation, and range of motion can elucidate additional musculoskeletal sources of pain.
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Before starting the pelvic exam, the providers should empower the patient to request a break or ask that the exam be concluded at any time. Provided adequate trust is established between provider and patient, in our experience, very rarely is it impossible to complete pelvic exams in patients with chronic pelvic pain, despite the high prevalence of sexual abuse and trauma in these women.
Begin the exam with external inspection and test for provoked and unprovoked vulvodynia through light palpation with a Q-tip. A single-digit internal exam with palpation of the urethra, obturator internus, bladder base, rectum, levator ani, anterior and posterior cul-de-sac and uterosacral ligaments, in addition to palpation of the uterus and adnexa is essential to identify the many possible sources of pain. With palpation of each area, it is also important to clarify with the patient if what she is feeling is the same pain she wanted evaluated because pain produced on pelvic exam often is not experienced in daily life.
Pelvic ultrasound is not indicated for all patients but should be considered in the presence of uterine or adnexal tenderness, or if the pelvic exam is limited secondary to patient habitus. Laboratory evaluation is rarely indicated, except to address specifi c symptoms or exam fi ndings. Diagnostic laparoscopy is common for evaluation of chronic pelvic pain, despite limited data supporting its use. Given the relatively poor correlation between intraabdominal fi ndings at time of laparoscopy and the extent of symptoms, diagnostic laparoscopy should be reserved for patients with known pathology by ultrasound, or in patients in whom endometriosis is suspected, but who do not respond to or cannot tolerate a trial of hormonal therapy.
Management
Multiple studies have demonstrated the effi cacy of a multidisciplinary approach to treatment of chronic pelvic pain.
7,16,17 Th e decision to refer for care by another provider should be based on local resources and provider ex- For endometriosis, continuous combined or progesterone-only oral contraceptives (OCs) remain fi rst-line treatment. Setting clear expectations about possible side eff ects is important, as is counseling patients that it make take 2 to 3 months of treatment for their pain to improve. Patients whose pain doesn't respond or responds inadequately to initial therapy should be evaluated further with laparoscopy to confi rm the diagnosis and potentially relieve symptoms. Once the diagnosis is confi rmed, treatment for endometriosis should be primarily medical with either ongoing continuous OCs, or one of several evidence based second-line therapies (Table 4) .
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Suspected interstitial cystitis should prompt a urinalysis and culture to rule out urinary tract infection and then, if feasible, the patient should be referred to a urogynecologist. Th ese subspecialists are well-equipped to not only make this diagnosis, but also to evaluate and treat commonly related diagnoses, such as overactive bladder syndrome, urinary incontinence, and pelvic organ prolapse. Patients can be given a list of common bladder irritants and asked to sequentially eliminate each from their diet and maintain a symptom diary in preparation for their consultation. A helpful patient handout is available from the American Urogynecologic Society (https:// www.augs.org/assets/2/6/IC.pdf ). A treatment guide from the American Urological Association may be helpful in cases where referral to a urogynecologist is not possible.
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Irritable bowel syndrome is highly likely in patients with chronic pelvic pain who have bowel symptoms. However, as with painful bladder syndrome, it is important to rule out other more serious conditions prior to settling on this diagnosis. "Red fl ag" symptoms (Table 5) should prompt consideration of alternative diagnoses or referral to a gastroenterologist. In the absence of these concerning symptoms, the ROME II criteria 25 can be used to make the diagnosis. A practical treatment guide, including a patient handout, is available from the American Academy of Family Physicians (https://www.aafp.org/ afp/2002/1115/p1867.html).
Musculoskeletal etiologies of pelvic pain are exceedingly common and can be readily elicited by careful exam, as described. While levator ani or obturator internus myalgia can be a primary cause of chronic pelvic pain, pelvic myalgia is more often due to chronic muscle contraction and subsequent injury in response to other painful stimuli. In addition to treating the other source(s) of pain, pelvic physical therapy is highly effective, with one study suggesting that about two-thirds of patients can expect mod-
Therapy Dosing Source
Leuprolide with add-back therapy 27 Th e American Physical Therapy Association maintains a registry of physical therapists that is searchable by zip code and area of expertise (aptaapps.apta.org/fi ndapt/ SearchResults.aspx).
A signifi cant proportion of patients who report chronic pelvic pain will have physical exam findings in the abdominal wall consistent with a trigger point, which has been defi ned as a focus of hyperirritability in a tissue that, when compressed, is locally tender and, if suffi ciently hypersensitive, gives rise to referred pain and tenderness, and sometimes to referred autonomic phenomena and distortion of proprioception.
28 While much controversy continues to surround this phenomenon, a trial of self-massage to the point of moderate discomfort has been proposed as a low-risk, potentially effective intervention. For patients in whom 2 to 3 weeks of self-massage has proven to be ineff ective, a trial of trigger point injections could be considered. 29, 30 Th ere are many variations in technique, though one example can be found here: https://emedicine. medscape.com/article/1997731-technique. In our clinic, a weekly series of three to four injections of 3 to 5 mL of 0.25% bupivacaine into the area of tenderness in the abdominal wall, low back, or pelvic fl oor muscles often provides signifi cant relief. If there is no response after the third or fourth injection, consider alternative treatments.
Given the known role of psychosocial factors in modulating central pain processing, these comorbidities should be treated concurrently with evaluation and treatment of peripheral sources of pain. Delaying management of anxiety, depression, and social stressors until after a trial of treatment of peripheral sources of pain is likely to result in decreased treatment efficacy and can often lead to the patient feeling dismissed. Any plan for referral should be a shared decision with the patient, with the discussion focusing on the role of both peripheral and central pain processing in the patient's overall pain experience. Developing a referral network of providers with expertise in pharmacologic management of depression, anxiety, and PTSD, as well as provision of counseling services will greatly bolster treatment effi cacy and likely provider and patient satisfaction.
What about opioids?
In 2015, there were 20,101 overdose deaths related to prescription pain medications; nearly double the deaths related to heroin. 31 For the retrospective cohort study, described in a researcher letter, visits to two EDs by adolescents aged 13 to 19 were analyzed. Th e focus was on encounters associated with a diagnosis of pelvic infl ammatory disease (PID) for which outpatient antimicrobial treatment was prescribed between January 1, 2016 and December 31, 2017.
Th e primary outcome of the study was prescription fi lling of STI-related antimicrobial treatment and secondary outcomes included patient-level and visit-level factors associated with prescription fi lling. Filling data were acquired through a program in the hospital's electronic health record that collects data from participating pharmacies and insurance plans. 
BENCH TO BEDSIDE by JUDITH M. ORVOS, ELS
Results of a prospective study combined with a meta-analysis suggest that cell-free DNA (cfDNA) testing for trisomy 21 (Down syndrome) may be just as eff ective in twin pregnancies as in singletons. Th e research also showed that in twin pregnancies, the noninvasive testing is superior to use of combined testing in the fi rst trimester or secondtrimester biochemical testing.
Published in Ultrasound in Obstetrics and Gynecology, the fi ndings are from a prospective study and meta-analysis by European authors. Th ey sought to assess performance of cfDNA testing for trisomies 21, 18 and 13 in twin pregnancy.
The data for the prospective study were from screening at 10 +0 and 14 +1 weeks in 997 twin gestations in two groups. Th e fi rst group were women who self-referred for screening to institutions in London or Brussels. Th e second group were women selected for cfDNA testing after routine fi rst-trimester combined testing at one of two National Health Service hospitals in England.
Th e authors also performed a metaanalysis of peer-reviewed publications on clinical validation or implementation of cfDNA testing for trisomies 21, 18 and 13 in twin pregnancy. Assessment of the literature and results from the prospective study were combined to determine cfDNA test performance.
In the prospective study, the researchers found that cfDNA testing correctly classifi ed 16 of the 17 cases of trisomy 21 (94.1%), nine of 10 cases of trisomy 18 (90.0%), and 962 of 968 cases without any trisomy (99.4%). Combining data from seven relevant studies, the pooled weighted detection rate (DR) and false-positive rate (FPR) for trisomy 21 were 98.2% and 0.05%, respectively. For trisomy 18, the DR and FPR were 88.9% and 0.03%, respectively, and for trisomy 13, they were 66.7% and 0.19%, respectively.
Th ere were too few cases of trisomies 18 and 13, the authors said, to accurately assess the predictive performance of cfDNA testing. For trisomy 21, they concluded that their results show that "performance of the cfDNA test is superior, both in terms of higher DR and substantially lower FPR, to that of the fi rst-trimester combined test or second-trimester biochemical test" in twin pregnancy. Clinically, the authors said, the results are "particularly important in the case of dichorionic twins in which both the incidence of aneuploidy and the invasive procedure-related risk of pregnancy loss are increased compared to in singletons. " For the retrospective populationbased cohort, de-identified administrative health data on all hospital visits between 2004 and 2017 from Alberta Health Services in Canada were examined. Using Canadian Classifi cation of Health Intervention codes, the researchers identifi ed women who underwent mesh midurethral sling placement and tracked whether they needed revision surgery, which was the primary outcome of the study. Th ey also recorded exposure including the annual number of midurethral sling procedures performed by a surgeon, surgeon specialty, facility type, patient age, and concomitant prolapse repair.
Of the 21,028 women who received a midurethral sling for urinary incontinence during the 13-year study period, 1,517 underwent a concomitant mesh procedure for pelvic organ prolapse (POP). Th ose cases were censored from the fi nal dataset, resulting in a sample size of 19,511 women. Mean follow-up for participants was 6.78 ± 3.59 years.
Cumulative rates of revision surgery were 3.84% (95% CI 3.54-4.17) at 5 years and at 10 years the rate increased to 5.26% (95% CI 4.82-5.74). Th e most vulnerable window for revision was the fi rst year after placement, with 0.40% (95% CI 0.31-0.49) undergoing revision within 30 days and 2.15% (95% CI 1.95-3.52) within 1 year.
Surgeon experience was associated with revision, as was concomitant prolapse surgery. However, after 50 cases per year, odds of revision declined with each additional case (OR 0.99/case, 95% CI 0.98-0.99; OR 0.91/10 cases, 95% CI 0.84-0.98). Th is decline plateaued at 110 cases per year. Surgeon specialty, hospital type, and patient age were not associated with outcome.
Revision surgery occurs in just a small proportion of women undergoing midurethral sling placement but each surgery comes with risk. Th e authors believe that this study is important because it can help identify ways to reduce risk and patients who might be at increased risk. Because the data point to a period of time when most repair surgeries occur, physicians may want to pay closer attention to their patients during the fi rst year after sling placement. 1 Now, the life expectancy is approximately 50 years.
Ben
1 Girls born with SCD in this century can expect to live to and through their childbearing years. Th eir blood disorder, however, presents unique challenges at every life stage that ob/gyns need to know how to manage.
Etiology of SCD
SCD is an autosomal-recessive disease characterized by presence of sickled red blood cells (RBCs). Sickled RBCs form in an individual who is homozygous for the sickle hemoglobin (HbS) gene (SS genotype) or is heterozygous for HbS and has another abnormal hemoglobin such as hemoglobin C (SC genotype), beta thalassemia (S-beta thal+ or S-beta thal 0 genotype), or some other rare hemoglobin. HbS has a single amino acid substitution of valine for a glutamic acid in the beta chain of the hemoglobin molecule, which prevents hemoglobin from forming neat tetramers. Instead the hemoglobin forms long, fi brous polymers that distort RBC membranes. Th ese distorted RBCs are readily destroyed by the reticuloendothelial system. Th e normal life span of sickled RBCs is approximately 15 days compared to the 120 days of normal RBCs. 2 Consequently, individuals with SCD suff er from moderate to severe anemia. Table 1 lists the prevalence of various genotypes derived from California newborn screening data 2 and the severity of the various genotypes.
3 Th e SS genotype (which accounts for more than half of the aff ected individuals in the United States) and the S-beta thal 0 genotype generally result in a more severe phenotype described as "sickle cell anemia." Th e other genotypes do not usually result in severe disease.
Anemia is not the only mechanism of the disease. Lysed RBCs release free hemoglobin, which consumes nitric oxide and leads to endothelial damage and possibly thrombosis. Membrane receptors become rearranged on the distorted RBC surface, altering its adhesive properties. Th ese altered RBCs interact with the endothelium, white blood cells, and platelets, and contribute to intravascular congestion, thrombosis, and downstream ischemia, resulting in both acute and chronic tissue damage. Forty years ago, 50% of children in the United States born with SCD also died before adulthood and 30% died before their fi fth birthday, 3 but since the 1970s, newborn screening programs, institution of penicillin prophylaxis, vaccinations against encapsulated organisms, and disease-modifying therapy with hydroxyurea have led to a dramatic decline in childhood mortality. SCD is no longer a life-threatening disease of childhood, but now a chronic disease of adults. 
Epidemiology of SCD
Consequences of SCD
SCD aff ects almost every organ and organ system, as shown in Table 2 . Acute complications of the disease are listed in Table 3 . Of particular concern to ob/gyns are the maternal and fetal consequences of SCD. Pregnancy complications are summarized in Table 4 . During normal pregnancy, there is a demand for increased erythropoiesis. Because women with SCD are already anemic, 30% to 40% require transfusion during pregnancy.
4,5,9 During normal pregnancy, women have an increased susceptibility to certain infections. Th e risk of infection is compounded in women with SCD. Compared to women without SCD, infectious morbidity is increased 2-to 13-fold. During normal pregnancy, women have an increase in glomerular fi ltration. Pregnancy has the potential to further impair renal function in women with sickle cell nephropathy. Normal pregnancy results in an increase in cardiac output. In a woman with SCD, the increased cardiopulmonary demands of pregnancy are potentially life-threatening, especially in women with SCD-induced pulmonary hypertension. Pregnancy results in an increased risk of thrombosis. In women with SCD who are already at high risk of VTE and stroke, pregnancy increases the risk of thrombosis 2-to 5-fold compared to women without the disease. Preeclampsia is increased 6-to 8-fold in women with SCD and maternal mortality is increased 6-fold, compared to women without SCD.
6,10 Fetal growth appears to start out normally, then lags after 25 weeks' gestation.
7 Fetal consequences of SCD include a 2-fold increased risk of preterm birth, 6 a 3-fold risk of small-for-gestational age, 6 and a 4-fold increased risk of stillbirth.
6
Diagnosis
Diagnosis of SCD within the first 3 months of life allows for early treatment. Since 2006, every state in the United States has had a newborn screening program for the disease. A study conducted in California found that overall mortality for children who were diagnosed after they presented with symptoms was 8%, compared to 1.8% after early identifi cation of SCD through screening and accompanying education of providers.
3,11
Treatment
Treatment for SCD consists of preventing complications, managing pain, modifying the disease, or attempting a cure. Prevention of complications includes prophylactic penicillin for children to prevent sepsis and meningitis from encapsulated bacteria, and vaccinations against Streptococcus pneumoniae (pneumococcus) and Haemophilus infl uenza.
3 Individuals with SCD are particularly vulnerable to these encapsulated bacteria due to functional or surgical asplenia. Chil- Managing the acute and chronic pain of SCD is challenging. Th e mainstay of pain management has been opioids, but nonsteroidal anti-infl ammatory drugs (NSAIDs) have also been used. Particularly for management of chronic pain, amitriptyline, gabapentin, selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), and complementary therapies have also been helpful. Disease-modifying therapy includes hydroxyurea, which raises fetal hemoglobin levels and reduces incidence of vaso-occlusive crises and episodes of acute chest syndrome. Hydroxyurea has been found to cause birth defects in animals, but has not been found to increase risk of birth defects in humans. 13 Nonetheless, hydroxyurea has generally been avoided during pregnancy. L-glutamine has recently been approved for prevention of vaso-occlusive crises, but there is little experience with this medication. 13 Other disease-modifying therapies are currently in development, but have not been approved for use.
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Cures of SCD have been accomplished with hematopoietic stem cell transplantation (HSCT) and now with gene therapy.
14 For HSCT, the donor may be related (e.g. a sibling) or unrelated. Related donors can be human leukocyte antigen (HLA) histocompatibility-matched (typically at 8/8 HLA loci) or haploidentical (matched at half of HLA loci). Originally only matched donors were considered, but now successful transplants have occurred with haploidentical donors as well. In preparation for HSCT, recipients receive chemotherapy or radiation. HCST off ers a cure, but can result in death, graft rejection, graft versus host disease, and sterility. 3, 13 After HSCT, a high proportion of young women do become amenorrheic and are presumed infertile. Gene therapy for SCD 15 is still experimental but there are three clinical trials underway. Subjects receive their own genetically modifi ed hematopoietic stem cells. In preparation, however, they still require gonadotoxic chemotherapy with the same potential risks to fertility as those with HSCT. Delay in menarche is not uncommon in girls with SCD. Several studies have reported on delayed menarche among girls with the disease. 16 A longitudinal cohort study of girls from infancy to young adulthood in Jamaica found that compared to controls, girls with SC genotype had a delay in mean age at menarche of 0.5 years and girls with SS genotype had a delay in mean age at menarche of 2.4. 17 Th is patient's ability to distinguish menstrual pain from the pain with vaso-occlusive crises is also not uncommon. Women with SCD do report distinct diff erences in the pain of menstruation compared to the pain with vaso-occlusive crises.
CASE 1 Menstruation and contraception in young women with SCD
18
Management of primary dysmenorrhea includes hormonal contraceptives and NSAIDs. In SCD, NSAIDs may increase vascular, bleeding, and renal risks, which may be compounded in patients with end-organ co-morbidities. For patients with SCD without a contraindication, however, NSAIDs are acceptable.
12 Hormonal therapy can reduce blood loss and pain with periods (a potential benefi t in SCD), but combined hormonal contraceptives increase risk of VTE and stroke 19 (a potential hazard in SCD). Depot medroxyprogesterone acetate (DMPA) injections have also been shown to increase risk of VTE, 16 but other progestin-only contraceptives do not. 16 In women with SCD, a systematic review of four studies showed no increased risk of VTE among those who used 20 Obviously, no combined hormonal contraceptives should be prescribed to a young woman with a history of stroke or VTE. Common sense further dictates progestin-only contraceptives be prescribed to a woman with SCD over combined hormonal contraceptives whenever possible.
Anticipation of HSCT
Th e fi rst published case 14 of a young woman referred for HSCT describes a scenario that has become more frequent. Th is patient was a 19-year-old young gravida 0 with SS genotype. She had a history of multiple episodes of vaso-occlusive pain crises and acute chest syndrome. Fortunately, her sister was an HLA match. She was referred to a reproductive endocrinologist who counseled her and her family regarding the options for cryopreservation of:
• embryos (created with donor sperm), which allows for preimplantation genetic testing (PGT) • oocytes, and • ovarian tissue -still experimental, but the only option for prepubescent girls. A low-dose ovarian stimulation protocol was used. Enoxaparin 30 mg subcutaneous every 12 hours was administered during stimulation and held 24 hours before egg retrieval. Eight mature oocytes were vitrifi ed (rapidly cooled to prevent formation of crystals). No reports exist about whether this patient has pursued a pregnancy successfully, but thousands of women without SCD have had successful pregnancies after oocyte preservation. 21 Also, while ovarian tissue preservation is considered experimental, more than 87 subsequent pregnancies have been reported, including two in women with SCD (one using her own ovarian tissue and another using her sister's). 3 
CASE 2 Preconception counseling
A typical case: A 28-year-old gravida 0 with SCD with SS genotype is referred by her hematologist because she will be married soon and is planning a pregnancy. She is currently taking hydroxyurea. Her partner does not think he has sickle trait or beta thalassemia minor, but he is not certain.
Th is patient's partner should be referred for testing. If he has abnormal Hb, the couple should be referred for genetic counseling and they should be aware of the option of PGT with in vitro fertilization. A type and screen should be reviewed or obtained. If antibodies are present that are known to cause hemolytic disease, the partner should be tested for the corresponding antigen(s). Th e patient should be counseled regarding the maternal and fetal risks of SCD in pregnancy. Although the risk of maternal mortality is increased, the absolute risk of maternal mortality is about 1%, 22 which does not discourage most women and their families from pursuing a pregnancy. The patient's medications should be reviewed and before a prenatal vitamin is prescribed, her ferritin should be checked. If the level is elevated, which is very likely if the patient has received transfusions, she should receive a prenatal vitamin WITHOUT iron (such as prenatal gummies). In addition, the American College of Obstetricians and Gynecologists recommends 4 mg of folate per day for women with SCD. 23 With respect to hydroxyurea, the patient should have a consultation with a maternal-fetal medicine specialist. After consultation 
Complications
SICKLE CELL DISEASE
with that specialist and a hematologist regarding risks and benefi ts, some patients may elect to continue hydroxyurea during pregnancy or at least until conception, stop for the duration of pregnancy, or stop it temporarily and restart it after the fi rst trimester. Once pregnancy is established, a patient with SCD should be cared for with the help of specialists in maternal-fetal medicine and hematology who have expertise in SCD. In early pregnancy, this patient's partner should have been off ered testing. If he had abnormal Hb, the couple should have been referred for genetic counseling and made aware of the options for prenatal diagnosis. He also could have been tested for the C red cell antigen. Anti-C antibodies are a rare but documented cause of hemolytic disease of the newborn. 24 If the partner were negative, the fetus would not have been at any risk for alloimmunization.
CASE 3 Pregnancy
A typical case: A 32-year-old gravida 3 para 1011 (one term pregnancy and one miscarriage) with SCD (SS genotype) at 36 weeks' gestation has worsening fetal growth restriction (FGR), which is now at the fourth percentile. Amniotic fl uid volume is low normal and the umbilical artery Doppler S/D ratio is normal. Th e patient has been hospitalized al-
Because of the increased risk of preeclampsia, low-dose aspirin was started at 12 weeks' gestation. Because of the increased risk of infection, monthly urine cultures were ordered. Th e patient's hemoglobin was monitored. A Hb of 8 g/dL was targeted and a Hb of > 7 g/dL was maintained for most of the pregnancy. Th ere is no good-quality evidence that a strategy of prophylactic blood transfusion does or does not benefi t the mother or fetus when compared to selective transfusion. 25 Whatever the transfusion strategy, the benefi ts of transfusion need to be balanced against the risks of alloimmunization and delayed hemolytic transfusion reactions, which can be life-threatening. 26 Because of the high risk of FGR, fetal growth was monitored with serial ultrasounds. 23 Our practice is to start at 24 to 28 weeks' gestation. Due to the increased risk of stillbirth, a plan for fetal surveillance was also in place. Our practice is to start antepartum testing at 32 weeks' gestation. If all is going well, we plan to deliver women with sickle cell anemia (SS and S-beta thal 0 genotypes) at 37 weeks' gestation and women with other genotypes at 39 weeks. For the patient on opioid medication, the nursery needs to be prepared for neonatal withdrawal syndrome. During hospitalization, there should be a plan for VTE prophylaxis. It is our practice to prescribe prophylactic doses of low-molecularweight heparin for 6 weeks postpartum.
Case 3 continued
Th is patient was transfused with 2 units of RBCs prior to induction of labor. She delivered a 2400-g infant vaginally. Postpartum, she received thromboprophylaxis with enoxaparin. She planned to use a longacting reversible contraceptive and restart hydroxyurea postpartum.
Menopause
For a variety of reasons, women with SCD may be at risk of early menopause or even premature ovarian failure, but there are essentially no data about menopause in these patients. 13 With a life expectancy of 50 years, however, women with SCD will need the help of gynecologists to manage menopausal symptoms.
Conclusion
Increasing therapeutic options for women with SCD and a longer life span are changing how ob/gyns care for women with SCD. For more information please visit the website for the Foundation for Women and Girls with Blood Disorders at www.FWGBD.org. When a patient is interested in having the device removed, her physician needs to examine several factors before deciding on a surgical approach.
by CHARISSE M. LODER, MD, MSC, AND SHEILA FLAUM, DO
T he recent removal of Essure from the US market has created concern among patients with the device about the reason for the manufacturer's action. Many women also may have questions about whether to have the device removed. Th is article reviews the history, literature, and symptoms related to Essure as well as removal techniques to guide physicians through the counseling process.
Essure background
Essure is a hysteroscopic sterilization technique involving placement of nickel-titanium microinserts in the fallopian tubes. Over the course of 12 weeks, the microinserts cause fibrosis and occlusion of the fallopian tubes. Essure was approved by the US Food and Drug Administration (FDA) in 2002. 1 Benefi ts of the technique were that it was a minimally invasive procedure that could be conveniently performed in the offi ce without requiring general anesthesia or abdominal incisions and hormone-free sterilization. It was a safe option for women who had contraindications to general anesthesia or hormonal contraception or who wanted to avoid abdominal surgery.
Concerns about Essure
Increasing patient reports about Essurerelated symptoms led to a growing number of safety concerns about the device. Patient concerns have ranged widely from hair loss to physical and mental disabilities. 2 One retrospective cohort study found that the most commonly reported symptoms following Essure placement were abdominal pain, back pain, fatigue, leg and hip pain, dysmenorrhea, and heavy menstrual bleeding. 3 Another retrospective case series revealed that pelvic pain, abnormal uterine bleeding (AUB), and a reported allergic reaction were the symptoms most commonly reported by women prior to undergoing Essure removal. 4 Patients who reported allergic reactions prior to sterilization were at higher risk of developing an allergic reaction with hysteroscopic sterilization when compared to laparoscopic sterilization.
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Websites and Facebook groups run by women with Essure who had symptoms, led to a public outcry against the device, specifi cally in regards to the polyethylene terephthalate (PET) fi bers in the microinserts. 6, 7 In response, in 2015, the FDA appointed a special panel to investigate these claims, added a "black box" warning, and created stricter guidelines for placement. 1 Continued complaints and stricter guidelines caused a significant decrease in the number of devices placed. 8 Bayer removed Essure from the European market in September 2017 3 and from the US market in December 2018 due to the decrease in sales. 1 In its announcement, Bayer stated that preventative removal for those without symptoms was unnecessary. history. Patients may report multiple symptoms that may or may not be associated with the device and each should be documented and assessed. For each symptom, we recommend determining whether it is localized or generalized and identifying the timing of onset, severity, aggravators, or relievers. Patients may experience symptom onset from immediately to several years after Essure placement. We recommend documenting treatment attempts, including non-pharmacologic and pharmacologic treatments. In addition, because patients may also seek care from other consulting providers-such as allergists, rheumatologists, gastroenterologists or neurologists-it may be beneficial to collaborate with these consultants to determine a care plan.
Of⇒ ce exam and work-up
For symptomatic patients, we recommend a detailed physical exam with a pelvic exam. It is particularly important to use a systematic approach to an abdominopelvic exam in cases of pain-related symptoms prior to surgery to eliminate other causes of pelvic pain. Th is type of exam includes an abdominal exam and may start with assessment of sensation with light touch or a pinprick. Next, lightly palpate to help identify any trigger points related to myofascial pelvic pain syndrome. Next, deep palpation can assess for any masses or hernias. Finally, assess for Carnett's sign, which if positive, suggests an abdominal wall etiology. Pelvic exam should fi rst include a Q-tip test along the external genitalia to evaluate for vulvodynia and assess sensation. Next, proceed with internal palpation of the obturator internus and levator ani to evaluate for pelvic fl oor myofascial pain. A bimanual exam can assess uterine size and adnexa. Finally, perform a speculum exam to observe for anatomic abnormalities or evaluate for infectious etiologies. Additional laboratory studies may be helpful in some patients. We recommend a work-up for AUB, which may include a complete blood count, thyroid screening, Pap test, and assessment of the endometrium with an endometrial biopsy. Transvaginal ultrasound (US) is helpful for diagnosis and surgical planning to evaluate uterine size, uterine structural abnormalities, or any adnexal masses.
In asymptomatic patients who present with concerns about safety of Essure following removal from the market, conversation and detailed education is necessary. A pelvic exam may or may not be indicated.
A range of imaging techniques can be used to evaluate microinsert placement, including ultrasonography, hysterosalpingography (HSG), and abdominal pelvic x-ray. Imaging can confi rm placement of the device and may inform counseling regarding device removal or surgical technique. We recommend ultrasonography, as it may elucidate other causes of symptoms such as fi broids, endometrial polyps, or ovarian cysts such as endometriomas. In addition, ultrasonography may also show perforation of the device through the uterus or fallopian tubes. HSG and x-ray imaging can confi rm tubal occlusion and evaluate the implants, with the possibility of revealing fractured implants.
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Surgical techniques
Several techniques for removal of Essure have been documented, including use of hysteroscopy, laparoscopic salpingectomy, cornuectomy, and total hysterectomy.
5,11-13 Th e type of removal chosen may depend on a patient's symptoms and comorbidities, and the surgeon's skill and experience. When discussing surgery with a patient, it is important to elicit her concerns, including preference for an approach, recovery time, and desire for en bloc removal. Because most patients with Essure want permanent sterilization, we do not discuss fertilitypreserving techniques here.
Hysteroscopic Essure removal can be an option up to 6 weeks after placement, before tubal occlusion has occurred.
14 Th is method of removal can be performed in situations of acute postprocedural pain and may help avoid abdominal surgery. Hysteroscopic removal also can be performed in conjunction with a laparoscopic salpingectomy to ensure removal of all fi laments. 
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Laparoscopic bilateral salpingectomy has been well-documented as a removal method; however, there is a theoretical risk of incomplete removal. 13 Th is approach can often be performed with three 5-mm laparoscopic ports. Th e surgeon makes an incision in the fallopian tube with electrocautery approximately 1 cm from the cornua. Th e Essure device is then grasped and gentle traction is used to remove both the outer and inner coils from the cornua. Next, electrocautery is used along the mesosalpinx to remove the fallopian tube.
15 Postoperative recovery time is usually 2 to 4 weeks. Benefi ts of this approach include the ability to diagnose and remove any pelvic pathology, that could also be contributing to the patient's symptoms. Th is technique, however, has the potential to leave fragments of the microinsert device, PET fi bers, in the pelvis or in the uterus as the microinsert is pulled from the cornua. In addition, we counsel patients that they may require another surgery if their symptoms continue postoperatively.
Laparoscopic cornuectomy with bilateral salpingectomy, an approach used to remove the microinsert and fallopian tubes en bloc, requires a laparoscopic surgeon trained in cornual wedge resection. It may require a 10-mm and two 5-mm laparoscopic ports, vasopressin for hemostasis, and suturing of the cornua in multiple layers. Although this technique has increased risks, including blood loss, 34 patients may benefi t from complete removal of the device. It may also be helpful in patients with symptoms concerning for allergic reaction. Patients may require 4 to 6 weeks for recovery.
Hysterectomy with bilateral salpingectomy will also remove the Essure inserts and can be done vaginally, laparoscopically or abdominally. Th is technique may be desirable for patients who also have symptoms of AUB and/or adenomyosis. Hysterectomy has the greatest surgical risk of all Essure removal techniques, including infection, hemorrhage, and ureteral injury. Recovery time for this method is the longest, at 6 to 8 weeks. 4 In one study of women who underwent gynecologic surgery following Essure placement, hysterectomy was the most commonly performed surgery.
12 Th is may be because it is the most likely to treat multiple symptoms, including Essure-related allergy, pelvic pain, and AUB.
Discussing postoperative outcomes
Several case studies and prospective and retrospective research have looked at symptom relief after Essure removal. Studies have reported that 40% of patients have complete resolution of symptoms when followed up to 3 years after removal via hysteroscopic, laparoscopic and laparotomy removal. 3 Th is unfortunately means that most patients do not have complete resolution of symptoms after removal. In addition, 10% to 15% reported no change in symptoms, with abdominopelvic pain being the most commonly experienced symptom prior to and following the surgeries previously mentioned. 3 Another study showed 75% improvement in quality-of-life following surgery, which was similar for patients undergoing laparoscopic bilateral salpingectomy or hysterectomy for removal. 4 A number of case series have proven that patients with previous nickel allergy or who develop allergy after Essure placement have improved outcomes after laparoscopic or hysteroscopic removal. 16 In a followup study of medical outcomes after sterilization, there was no diff erence in risk of developing an autoimmune disease with hysteroscopic versus laparoscopic sterilization.
One diffi culty in assessing surgical success is that it may also be hard to distinguish between resolution due to removal due to placebo eff ect.
Patient-centered care
Patients with the Essure device may present with or without symptoms related to the microinsert. Women without symptoms should be counseled that they do not need to have their coils removed and that removal could cause increased risk of injury. Symptomatic patients who want counseling about Essure removal should be worked up for the most common diff erential diagnoses for their symptoms. A thorough history and physical exam is crucial to identifying possible causes. Specific labs, imaging, and consultation with multidisciplinary consultants may also assist with diagnoses unrelated to Essure. Counseling regarding methods of removal and outcomes associated with them are necessary for shared patient decision-making to achieve a patient's desired outcomes. 
Conclusion
Chronic pelvic pain is a complex, often multifactorial condition that affl icts many women and poses a signifi cant challenge to our healthcare system. Evaluation should include a comprehensive history and physical with consideration for gynecologic and nongynecologic sources of pain. Practical, non-opioid-based treatments exist for the most common causes of chronic pelvic pain, which should be provided in concert with therapy for any co-existing psychosocial stressors. Opioids should be prescribed only after careful consideration and with patient safety in mind. While challenging, treatment of chronic pelvic pain can be rewarding and have a lasting impact on our patients' quality of life.
DISCLOSURES The authors report no potential con⇓ icts of interest with regard to this article.
FOR REFERENCES VISIT contemporaryobgyn.net/ChronicPelvicPain
Chronic pelvic pain CONTINUED FROM PAGE 16
Vacuum delivery CONTINUED FROM PAGE 11 delivered by vacuum extraction suggest that cognitive outcomes in this group are about equal to those delivered by unplanned cesarean delivery. In Australia, children were evaluated at age 8 and Hsieh et al. found that in singleton children born at term, instrumental delivery did not appear to have an adverse eff ect on neurodevelopment.
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Discussion
In the future, if women decide to have fewer children, tend to live longer, and expect a higher quality of life in older age, long-term consequences of vaginal and cesarean deliveries will have to be considered. Shared decision-making should become the norm. Th e physician-patient discussion in a problematic second stage will include discussion of immediate and long-term surgical risks due to cesarean section, balanced against risks of short-and long-term sequelae of anal sphincter and pelvic fl oor injuries related to an operative vaginal delivery. Th ese conversations are complicated at any time and might better be addressed prior to the onset of labor.
If we are to continue to off er vacuum deliveries as an alternative to cesarean deliveries for maternal or fetal complications in the second stage, we must be assured that our residents are adequately trained in the technique. At a time when experienced attending physicians skilled in forceps deliveries are rare, "on-the-job" training from these individuals may no longer be an option. Because use of vacuum extraction has had greater acceptance than forceps delivery due to the belief that less damage to the perineum is involved, and is perceived as an easier skill to acquire, there are still some opportunities for a resident to practice under the guidance of an experienced practitioner. However, simulation systems designed to practice vacuum extractions will increasingly need to be utilized to compensate for currently low numbers of this type of delivery. 42 We need to consider the possibility that operative delivery in general, rather than the instrument itself, is associated with OASIS and other pelvic fl oor injuries. 3 It may be that a prolonged second stage, which is increasingly common in modern obstetric management, is also implicated in increased incidence of these complications as noted by Ramm et al. 3 It is possible that whenever a procedure is necessary to eff ect prompt delivery, whether operative or cesarean delivery, in the second stage, there will often be some sequelae that may aff ect the mother, the neonate or both simply due to the fact that the labor is abnormal. Th erefore, an appropriate discussion with the patient about the likelihood of success and potential risks involved in the recommended procedure is imperative. 
DISCLOSURES
Building bridges T
here are no doctors in my family, and only a single nurse, my Aunt Frances. When I was accepted to medical school, she took me aside and made me promise to do one thing: Never take the nurses for granted.
I have always found the culturally accepted animosity between doctors and nurses baffl ing. Medical TV shows would have us believe the two groups are like animals from diff erent species, insisting we are preternaturally destined not to get along, that we come from diff erent worlds.
Frustrated with this concept and determined to heed my aunt's advice, I committed to do my utmost to buck this trend. At fi rst, it was easy. Th roughout my clinical rotations in medical school, I had no trouble befriending nurses and doctors alike; each group was as likely to cheer or chastise me. I hung out at the nurses' station almost as much as the residents' workroom. But during my fi rst month as an intern, I noticed something had changed.
A patient came in to the labor and delivery ward at term with decreased fetal movement. Her elevated labs and pressures in triage were consistent with preeclampsia with severe features. Her induction was started but, dulled by a magnesium drip, proceeded slowly. Eventually, though, she dilated to 6 cm and, expecting her to make some change in active labor, I dutifully reported to the nursing station to reexamine the patient. But the nurse was reluctant to accompany me to the patient's room. "She's been up all night, she's so upset, she feels awful on the magnesium, and it's only been a couple hours since you last checked. Can't you just give her a little longer?" I was confused. Th e patient's variability on fetal heart rate (FHR) monitoring was minimal, and she was in active labor. Her category 2 tracing was not dire, but it wasn't exactly reassuring given her preeclampsia. Th e American College of Obstetricians and Gynecologists Practice Bulletin I had stayed up the night before memorizing clearly stated she needed to be checked every 2 hours. And after all, this was hardly my decision. My attending and senior resident had instructed me to go assess the patient's labor. I was just doing what I was told.
With my aunt's words echoing in my ears, I pleaded my case as gently as I could to the nurse. She pleaded with me, too, insisting the patient needed rest. Eventually the charge nurse overheard our conversation and told her colleague she had to stick with protocol. As the nurse stood up to join me, she said quietly, "I'm just trying to advocate for my patient. " I was shocked. Wasn't I trying to advocate for the patient? And wasn't she "our" patient? I didn't want her to have an eclamptic seizure or a stroke, I didn't want her baby to spend his fi rst 24 hours of life in the neonatal intensive care unit. By the nurse presenting When a resident's promise to appreciate nurses is challenged, a conversation with one illustrates how both roles play an integral part in patient care. We arrived in the room and I did a cervical exam. Th e patient's condition remained unchanged. After placement of an intrauterine pressure catheter, and another hour of waiting, the patient was taken to the operating room for a cesarean delivery for arrest of dilation.
I was still upset about the nurse's words. By accepting the narrative that she and I had diff erent agendas for our patients, she only reestablished the supposedly natural, eternal confl ict between doctor and nurse I had been trying so hard to defy.
After that, I grew cynical. I stopped spending time in the nurses' station and instead retreated as often as I could to the physicians' workroom. I was cordial and friendly with the nurses, but I didn't go out of my way to make friends.
And then one day, a diff erent nurse stopped me in the hall of the labor and delivery fl oor to ask a question about a patient. "I have the patient in room 9, " she said. "Are you taking care of her?" "Yes, of course, " I said. "I'm taking care of everybody. " She looked confused. How could I be taking care of a dozen laboring patients at once?
Th is short conversation brought home two conclusions for me. First of all, this nurse and I had fundamentally diff erent defi nitions of the word "care. " Th e level of deep, committed, responsive care she was expected to provide was entirely diff erent from the clinical medical care I was off ering. I am hardly an automaton and endeavor to spend time getting to know my patients beyond their medical diagnoses. But it would be impossible for me, managing an entire labor fl oor, to have the same intimate relationship with every patient that the nurse could off er.
Second, I realized that neither of us really understood the other's job. I thought back to my conversation with the nurse who told me she was advocating for her patient. I had not realized then just how much time she had spent taking care of this patient, one-on-one, and how she had been this patient's source of comfort and reassurance. How could she not see herself as an advocate and a defender, especially against possibly unnecessary interventions from a doctor who was only able to visit this patient every few hours? I decided to quit holing myself up with the other physicians. Whenever I had a free moment, or a question about a patient, I resolved to go sit in the nurses' station and have an actual interaction. I began asking questions about the nurses' jobs, about the hundreds of varied tasks they were responsible for, things I had always taken for granted. While sitting there, I saw just how often they got up to check on their patients and how closely they monitored the FHR tracings in front of them. Likewise, they saw just how often my pager went off , summoning me to one of the many patients I was taking care of concurrently.
To be honest, expending that level of emotional eff ort can be exhausting. Unsurprisingly, it turns out that building bridges with colleagues can be as tiring as the work itself. Ultimately, however, I believe it is a valuable practice. By knowing one another as people, by fully understanding not only how alike we can be but just how vastly diff erent-and equally important-our jobs are, we begin to better understand how our roles complement each other.
And that is an important truth: the jobs are vastly diff erent. How else would we both be able to "advocate" for a patient and yet suggest completely diff erent management plans? But that is why doctors and nurses have been a part of the Western model of medicine since the nineteenth century: they both play roles on the spectrum of medical care. One could not function without the other.
In the "animal kingdom" of modern medicine, perhaps we're not so diff erent after all.
This nurse and I had fundamentally different de⇒ nitions of the word "care."
The level of deep, committed, responsive care she was expected to provide was entirely different from the clinical medical care I was offering.
Are you a current resident and interested in writing about your experiences?
Email COGEditorial@mmhgroup.com to learn more about becoming a resident blogger.
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Is it possible to make OB coding less complicated? J ust like our patients, proper coding and billing for obstetric patients can be…compli-cated. As a coding instructor and compliance auditor, I fi eld a lot of questions from new students and experienced billers alike. In this article, I'll break down a few of the most important concepts you need to understand to master obstetric coding.
The global period
Billing codes for maternity care and delivery are used to report antepartum care, vaginal or cesarean delivery, and postpartum care in uncomplicated pregnancies. Antepartum care includes the initial prenatal history and examination, subsequent prenatal history and examinations, recording of weight, blood pressures, fetal heart tones, routine chemical urinalysis, and monthly visits up to 28 weeks' gestation; biweekly visits to 36 weeks' gestation; and weekly visits until delivery. Delivery services include the hospital admission, management of uncomplicated labor, and cesarean or vaginal delivery (including episiotomy and repair if needed). Postpartum care includes visits in the hospital and a 6-week follow-up in the offi ce following
The sheer number of code options can be intimidating, but mastering a few concepts can alleviate some of the stress.
by MIKE ENOS, CPC, CPMA, CPC-I, CEMC
EXAMPLE CODING SCENARIOS:
EXAMPLE: A patient comes in for a routine prenatal visit at 28 weeks. An H&P is done along with a recording of weight, blood pressures, fetal heart tones, and routine chemical urinalysis. This is a global service and is not separately billable.
EXAMPLE:
A patient in labor in her 39th week is seen in the maternity ward.
The fetus is in a breech presentation. The provider performs an external cephalic version, turning the fetus into a head ⇒ rst position. This is not part of the global OB package, and may be billed separately with CPT code 59412. The diagnoses for the service would be O32.1XX0 Maternal care for breech presentation and Z3A.39 39 weeks gestation of pregnancy.
EXAMPLE: A pregnant patient presents to her obstetrician with a fever and nausea at 18 weeks. Lab results con⇒ rm a UTI. This is not part of the global OB package, and may be billed separately as an evaluation and management service (99211-99215) with a diagnosis of O23.92 Unspeci⇒ ed genitourinary tract infection in pregnancy, second trimester and Z3A.18 18 weeks gestation of pregnancy.
A patient returns to her ob/gyn 4 weeks after delivery complaining of fever and breast tenderness. She is diagnosed with mastitis associated with lactation. This is not part of the global OB package, and may be billed separately as an evaluation and management service (99211-99215) with a diagnosis of O91.23 Nonpurulent mastitis associated with lactation.
EXAMPLE: A patient vaginally delivers a single liveborn infant in the hospital.
Following the delivery, the patient develops elevated blood pressure and swelling of the hands and feet. She is diagnosed with Eclampsia and is followed-up closely in the hospital. The delivery was uncomplicated, and would be billed as 59400 with a diagnosis of O80 Encounter for full-term uncomplicated delivery and Z37.0 Single live birth. The eclampsia and associated follow-up are not part of the global OB package, and may be billed separately as an evaluation and management service (99221-99233) with a diagnosis of O15.2 Eclampsia complicating the puerperium.
PRACTICE MATTERS
JULY 2019
32 CONTEMPORARYOBGYN.NET CODING FOR OB delivery. It may also include services related to a cesarean delivery, such as an incision check.
When billing for maternity care and delivery, codes exist to bill the global package (antepartum care, delivery, and postpartum care) or for specifi c components in the event you are billing for a provider who performed the antepartum care only, delivery only, or postpartum care only.
Note that pregnancy confi rmation during a problem-oriented or preventive visit is not considered part of antepartum care and should be reported separately using the appropriate E/M code (for example an Outpatient Office Visit Code, 99201-99215). Also, remember that medical complications of pregnancy (eg, cardiac problems, neurological problems, diabetes, hypertension) and medical problems complicating labor and delivery management may require additional resources and should be billed separately -they are not included in the "global OB package."
Delivery coding
When it comes to billing for maternity care and delivery, the number of code options can be confusing. Simply put, there are codes to report the global package, or components of it (as discussed above) depending on the method of delivery. For example, 59400 is used to report Routine OB care including antepartum care, vaginal delivery, and postpartum care. Codes immediately following 59400 report individual components of the global package. Code 59510 reports Routine OB care including antepartum care, cesarean delivery, and postpartum care.
However, there's one more wrinkle that confuses some coders: Patients who have had a previous cesarean delivery and now present with an expectation of vaginal delivery have their own set of delivery codes, depending on the outcome. 59610 reports routine OB care including antepartum care, vaginal delivery, and postpartum care after a previous cesarean delivery. 58618 is used when the same patient with a previous cesarean attempts a vaginal delivery but delivers again via cesarean section.
ICD-10 concepts
With ICD-10 OB coding came a new set of billing guidelines that can be complicated, especially for newer coders trying to get acclimated to coding. Th e fi rst important consideration when selecting a diagnosis code is to read the Th at something is information overload.
To get a sense of sheer volume, as of March 2019, there were 679,747 articles on PubMed labeled "clinical trial." Th e number of medical sources continues to climb, and the reality is that new clinical research is coming out so fast doctors simply can't keep up.
And it's not that they don't want to. Th ey just don't have the time.
In a recent survey by Univadis of 550 physicians across four specialties-general medicine, cardiology, endocrinology, and oncology-64% said the time they spend keeping up to date in their field is insufficient. That number was higher for cardiologists (68%) and general practice (65%) doctors.
To peel the onion back one more layer, doctors are often fi nding limited value in investing their time in reviewing clinical research. According to the survey, 82% overall said that fewer than half of the studies they do read actually have an impact on how they practice medicine. Cardiologists (76%) felt the information they review was slightly more useful, and general practitioners (84%) felt it was less useful, but that makes sense given the breadth they have to keep up by COREY DEAN, MD, FACP, FAAP, CAQSM Practitioners are awash in volumes of research and information; good strategies help manage the deluge.
Managing information overload
WHAT CAN DOCTORS DO to stay up to date and manage the changing doctor/patient relationship?
Figure out your learning style: There are many ways to access information. Knowing whether you like to consume information through reading, listening to a podcast, experiencing it in person in a venue like a conference, or joining an online physician community will help you seek and retain information in the way that's best for you.
Choose your top sources: Given the volume and variety of sources, try to ⇒ gure out three to four go-to sources and consult those ⇒ rst. Trying to keep up with it all is a sure-⇒ re way to burn out.
Be humble: Doctors can't know everything, and in today's interconnected world, we don't have to. If a patient does present you with something you hadn't heard of-which happens to all doctors-thank them, let them know you'll look into it, and then follow through. You'll be approaching the information they brought up based on all your medical knowledge and can then let them know whether the source is reliable and explain your recommendation accordingly.
Build alliances and collaborations:
Interacting with fellow physicians, both at their institution and elsewhere, can generate knowledge and healthy debate on current medical research. There are many online physician communities ripe with insights about which research is actually impacting their practice of medicine.
Seek curated content: Doctors can also look to subscribe to a credible service that summarizes the latest research that is relevant to their ⇒ eld of medicine.
INFORMATION OVERLOAD
on. Th is begs the question that, in a profession with so many competing priorities, why would a doctor invest valuable time in something that won't ultimately elevate the level of care they bring to their patients?
While the volume of research increases, patients are changing as well. Th ey are web-savvy and spending time researching their condition. Th ey're showing up at their appointment more informed than ever, sometimes even surprising their doctors with new information.
In fact, 52% of doctors in the Univadis survey admitted that they've had patients present them with credible, relevant medical information they were unaware of. Th at's no surprise given the Internet and the speed at which new information is released. Th e fact is that in some cases, a patient with a specifi c diagnosis probably has more time to uncover every option than their doctor.
If nothing else, the Univadis survey demonstrates that the rise in the volume of clinical medical information is impacting the relationships doctors have with their patients and shifting the dynamic. But it will remain important for doctors to remain informed.
Information is certainly not going to slow down, so doctors should come up with a plan to keep up so they are ready to have informed conversations with patients. 
FROM THE PAGES OF
guidelines for each section. Th e ICD-10 guidelines state that codes for chapter 15 (Complications of Pregnancy, Childbirth, and the Puerperium) have sequencing priority over other codes from other chapters and are to be listed fi rst unless the pregnancy is completely incidental and has nothing to do with the reason for the visit.
Another important consideration is the fact that in ICD-10, most of the diagnoses in chapter 15 include the concept of trimester. Th e guidelines state that not only should you select the code with the appropriate trimester for the current encounter, but a separate code (Z3A.--) should be used to report the weeks gestation for the encounter. For example, a patient in her 16 th week of pregnancy should be assigned a code from chapter 15, followed by the code Z3A.16 to indicate 16 weeks' gestation.
Routine vs problem visits
For a routine outpatient prenatal visit when no complications are present, select a diagnosis code from range Z34, Encounter for Supervision of Normal Pregnancy, as the primary diagnosis. Remember that on average, the global OB package encompasses 13 routine visits during pregnancy, which includes routine visits in uncomplicated cases, and 6 weeks postpartum care. Th is may include H&Ps, routine measurements, and educational services such as breastfeeding or basic newborn care. Services that are not part of the global OB package may be billed separately, such as an initial evaluation and management service to diagnose pregnancy, amniocentesis, cephalic version, additional E&M services for unrelated reasons (e.g., asthma or urinary tract infection) or greater frequency of visits due to a high-risk pregnancy. Sometimes coders get confused and either miss out on billing a service that isn't included in the global OB package or they mistakenly try to bill for a visit that is included in the package.
Sometimes our patients (and our coding) can be routine, but other times things can get complicated. Having a good understanding of what is included can help you be prepared so that when you encounter a situation that isn't included, you don't forget to bill for it. It always helps to have your (heavily marked up and highlighted) coding manuals and/or cheat sheets nearby, and reimbursement policies from your offi ce's biggest payers on your computer. 
ULTRASOUND ERRORS
the fundal height and the estimated gestational age. Th e plaintiff 's expert witness testifi ed that the ultrasound report erroneously reported the estimated date of delivery, the primary obstetrician should have recognized this discrepancy and the persistent discrepancy in the fundal height and gestational age and ordered a repeat ultrasound.
THE VERDICT
The case settled for $980,000 prior to trial. 
LEARNING POINTS
The ⇒ nal written report is considered the de⇒ nitive means of communicating the results of an imaging study or procedure. Direct or personal communication must occur in certain circumstances, such as major fetal anomalies or ⇒ ndings that immediately impact management of the pregnancy. The primary obstetrician must read the entire report and correlate the ultrasound ⇒ ndings with the clinical ⇒ ndings. Inconsistencies require further investigation or imaging.
CASE 3 Be careful about what you DO NOT document.
A 33 year-old G3P2002 underwent an ultrasound at 19 and 1/7 weeks' gestation. Th e ultrasound reported stated, "Normal ultrasound with fetus at 19 1/7 weeks of gestation." No further ultrasounds were performed. At 39 weeks' gestation, the patient delivered a baby with Down syndrome. An expert review of the ultrasound revealed mild pyelectasis with calyceal dilatation of 4.3 and 4.4 mm. In addition, an echogenic intracardiac focus was identifi ed. At trial, the radiologist testifi ed that the practice rounds to the nearest whole number. Th us, the calyceal dilation would have been 4 mm and within normal limits. Further, an echogenic intracardiac focus is a worthless marker and of no consequence. Th us, the ultrasound was normal.
It is the obstetrician's duty to recommend further testing to the patient. Th e obstetrician testifi ed that the ultrasound was reported as normal and he had no reason to recommend amniocentesis or further ultrasound studies. Th e plaintiff 's expert testifi ed that calyceal dilatation > 4 mm at 19 and 1/7 weeks' gestation warrants a repeat ultrasound at 32 weeks to evaluate for persistence of the calyceal dilatation. As an isolated fi nding, an echogenic focus is poor marker for Down syndrome. However, when multiple soft markers for Down syndrome are identifi ed, they should be noted in the report and recommendations made to recalculate the patient's risk with amniocentesis, if indicated. A repeat ultrasound should have been recommended.
THE VERDICT
The jury found as follows: Obstetrician: Defense verdict Radiologist: Plaintiff verdict. The radiologist had a duty to report the ⇒ ndings to the obstetrician. If he had done so, the duty for further counseling, evaluation, and treatment would have transferred to the obstetrician.
Avoiding ultrasound errors
CONTINUED FROM PAGE 41
The ⇒ nal written report is considered the de⇒ nitive means of communicating the results of an imaging study or procedure.
reporting system can facilitate its inclusion in an ultrasound report.
Billing for both studies must be appropriate. For example, if an ovary not seen on TVUS could be visualized on abdominal ultrasound, it would be appropriate to bill CPT 76830 (Complete evaluation of the female pelvic anatomy-vaginal study) and CPT 76857 (Ultrasound, pelvic [non-obstetric], real-time with image documentation; limited or follow-up). 1 Billing for CPT 76856 (Complete evaluation of the female pelvic anatomy-abdominal study) should not be done unless all elements of the abdominal ultrasound are performed.
These elements include:
Description and measurements of uterus and adnexal structures
Measurement of the endometrium
Measurement of the bladder (when applicable)
Description of any pelvic pathology
In general, the code for a limited study, whether transabdominal or transvaginal, is the more common second code. It documents that the study did not include all elements of a complete study.
Inaccurate or inappropriate billing may present greater ⇒ nancial risk than medical liability. The physician is ultimately responsible for submitting the correct bill. Delegating coding for procedures increases the risk of error, for which the provider is liable. Electronic health records highlight another risk of possible fraudulent billing. Including the documentation for a management consult in the ultrasound report is not adequate for the purpose of billing an evaluation and management (E&M) code. Documentation in a separate progress note should be performed when billing an E&M code, in addition to the CPT code(s) for an ultrasound study.
Summary
Th ese cases illustrate common errors leading to litigation when performing obstetric and gynecologic ultrasound. Underlying each scenario is proper documentation of the ultrasound fi ndings. Findings should be recorded and results communicated consistent with the AIUM Practice Parameter for Documentation of an Ultrasound Examination. 2 Applying the discussed recommendations is no guarantee that a physician will not be held liable for such errors. Applying these best practices, however, will enhance the defensibility of such cases. 
ULTRASOUND ERRORS
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The importance of intervention
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The physician is ultimately responsible for submitting the correct bill. Delegating coding for procedures increases the risk for error, for which the provider is liable. 
MARKETPLACE
Ultrasound errors to avoid:
How important is the report?
CASE 1 Look at the images
A patient underwent four ultrasounds during her pregnancy. Th e sonographer remarked that in three of the studies, there were, "Structural irregularities that require further evaluation." Th e physician notifi ed the patient that the ultrasounds were normal. Th e baby was born with a midline facial defect, cleft palate, club foot, and lower-limb anomalies. Th e child has limited cognitive and communication skills. During litigation, the physician admitted that he had not reviewed the images from the studies or the sonographer's handwritten report about the fi ndings.
THE VERDICT
A $1.9 million settlement was reached prior to trial.
LEARNING POINTS
Unfortunately, it is not uncommon for physicians to rely on the sonographer's "report" and fail to personally review the images. Although sonographers are responsible for obtaining appropriate images, interpreting ultrasounds is beyond the scope of their professional practice. Interpretation of studies and associated recommendations are the responsibility of the physician. Physicians should review study images and either scan the patient themselves or refer the patient to an imaging specialist for further evaluation and diagnosis.
CASE 2 Documenting and reading the report carefully
A 28-year-old G3P2002 presented to her physician at 16 weeks, 4 days with a history of oligomenorrhea and two prior cesarean deliveries. Her estimated date of delivery (EDD) was 4/10/XX. Because of the woman's body habitus, the physician was unable to palpate the uterine fundus. Fetal heart tones were documented at 160 beats per minute. Th e patient was referred for an ultrasound, which was performed at 17 weeks' gestation by dates and consistent with 9 weeks, 4 days' gestation. Th e report stated, "Live, intrauterine pregnancy with a gestational age of 9 weeks 4 days + 6 days. Th e EDD is 4/10/XX. No abnormalities visualized." Th e EDD should have been 6/2/XX but the report showed the original EDD, rather than the new one. No further ultrasounds were performed during the pregnancy. On 4/05/XX, the patient delivered a 1710-g male infant via cesarean, who had Apgar scores of 9 and 9 at 1 and 5 minutes, respectively. Th e baby's Ballard score was consistent with 31 weeks. He suff ered unusually severe complications of prematurity with severe respiratory distress syndrome, bronchopulmonary dysplasia, and necrotizing enterocolitis requiring surgery.
Deposition of the defendant obstetrician revealed repeated exam inconsistencies and poor documentation. For example, the patient was seen for abdominal pain at 23 and 2/7 weeks by dates and 15 and 5/7 weeks by ultrasound. Th e only documentation of the examination was "Uterus is normal." Th ere were repeated discrepancies between Four cases illustrate common errors that can lead to litigation.
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■ Infertility in today's patients
Moderator: Your practices both focus signifi cantly on managing and treating infertility issues. How do the majority of your current patients end up in your practice? Dorette Noorhasan, MD: There are several ways that patients typically fi nd me. The fi rst is a direct referral from their ob/gyn. The second is a simple Internet search. The third is word of mouth from my prior patients who have had a good experience. Social media is also very important. There are insurance plans as well that direct patients to Centers of Excellence for infertility. Fortunately, at CCRM Dallas-Fort Worth, we are lucky enough to be a Center of Excellence.
Charles Miller, MD: When I was a younger man, it was virtually all via physician referral. Nowadays, while there are still a lot of physician referrals, many of my current patients come through referrals from their family or friends or through personal links to patient advocacy groups.
Moderator: In today's healthcare environment, do you fi nd that the majority of general ob/gyns will attempt to manage their patient's infertility issues on their own initially, or do most of them refer patients to specialists such as yourselves right from the start? Do you have a preference? Dr. Noorhasan: I'm OK with either approach. There are several physicians in my area who will refer patients directly to me, particularly patients with advanced reproductive age (≥35 years), abnormal fallopian tubes (tubal factor), or abnormal semen parameter (male factor). Some ob/gyns will try to manage infertility initially in younger patients and in those without abnormal testing, only sending these patients to me after they have failed approximately 3 cycles of ovulation induction with oral medications such as clomiphene citrate or letrozole.
Moderator: What are currently the most common causes of infertility you see in your practice? Dr. Miller: Successful fertility comes down to the sperm traveling to meet and fertilize the egg, and then the fertilized egg successfully implanting into the uterus. Thus, the causes of infertility are secondary to the following:
• Male factors, including sperm count and function • Cervical factors, namely the ability to create a conducive environment within the cervix to allow transport of the sperm from the vagina into the uterus • Egg factors, including folliculogenesis, ovulation, and luteinization • Pelvic factors, which allow ovum pick up, fertilization in the fallopian tubes, and implantation in the uterus In addition to these factors, endometrial polyps, submucosal fibroids, intrauterine adhesions, uterine malformation, and retained products of conception can also all lead to implantation issues aff ecting fertility.
Dr. Noorhasan: The most common cause of infertility that I see today is age-related. We're all waiting until later in life to have children-traveling the world, starting our careers, those types of things-and starting a family is often put on the backburner. And then, by the time it becomes a priority, there is a heightened risk of infertility issues.
There are also a lot of people I see in their late 30s or 40s who are on their second or maybe even third marriages, who have children from a previous marriage and thought they were done building a family. Maybe they had a vasectomy or had their tubes tied, but now they've met someone new and want to have another child. Infertility issues are common in that population as well.
■ Hysteroscopy: the basics
Moderator:
In general, what is the value of using a hysteroscope in an ob/gyn practice? Dr. Miller: In an ob/gyn practice, hysteroscopes give you the ability to not only diagnose but also often treat conditions related to abnormal uterine bleeding and some causes of pelvic pain. In a practice that focuses on infertility issues, a hysteroscope is an invaluable tool that allows providers to treat conditions related to abnormal uterine structures that may aff ect fertility.
Moderator: What are the benefi ts of a hysteroscopic approach in the diagnosis of intrauterine adhesions?
Dr. Miller: The hysteroscopic approach allows you to "peek and treat," in other words, to directly evaluate the severity of the adhesions and immediately treat under direct visualization. In the past, most ob/gyns would perform a blind dilation and curettage (D&C), which was really challenging because you couldn't assess the extent of adhesive disease or know if adhesiolysis was complete. By the same token, there was a risk of traumatizing areas of the uterine cavity where there was normal tissue. Using a hysteroscopic approach that allows you to see what is being treated is a tremendous improvement.
Moderator: What can be done in women with intrauterine adhesions?
Dr. Noorhasan: In women with mild intrauterine adhesions, you can perform operative hysteroscopy and take down the scar tissue fairly well without any additional assistance. With moderate-to-severe adhesions, many times we will do the hysteroscopy at the same time we are doing either an abdominal ultrasound or a laparoscopy to help guide the hysteroscopy. Sometimes, the scar tissue is so severe that you don't know where the anatomy ends, which mandates use of laparoscopy or ultrasound guidance to avoid a uterine perforation.
In our clinic, we typically have a second physician perform the laparoscopy or abdominal ultrasound and watch to make sure we are not going too far out in any direction as we are taking down the scar tissue, so that we stop once we have reached normal uterine tissue.
Dr. Miller:
A patient who develops intrauterine adhesions once is at signifi cant risk of recurrent adhesions, so it's important that you develop a clear strategy before the start of the procedure. The two edges of the uterus are juxtaposed, so that if you simply remove adhesions between the two walls-say from the anterior to the posterior wall-after you take out your instrument and the fluid leaves, those walls are once again juxtaposed and thus may fuse, causing adhesions. When there are signifi cant adhesions involving two edges of the uterus, we will often use a uterine stent to separate the edges for 5 to 14 days, as well as estrogen for 1 month to prevent those edges from fusing.
When removing intrauterine adhesions, it is important to minimize the use of energy applied during the procedure. The concern is that the excessive use of energy in the uterus can spread laterally and cause tissue necrosis. We treat our severe cases of lysis of intrauterine adhesions utilizing laparoscopy or ultrasound guidance.
Dr. Noorhasan: I will also insert an intrauterine stent or balloon and leave it in for 4 to 7 days after surgery to keep the uterus distended and prevent scar tissue from re-forming. Additionally, I will prescribe estrogen pills following surgery to help rebuild the endometrium. That's the area that is usually most signifi cantly scarred, so estrogen can help rebuild the endometrial lining.
In most patients with intrauterine adhesions, we are able to remove the scar tissue during hysteroscopy. Dr. Noorhasan: I perform a saline-infused sonogram as the initial screening test and follow up with a hysteroscopy if anything is abnormal, but hysteroscopy is generally considered the gold standard. 2, 3 In 95% to 99% of all cases, my experience is that a saline-infused sonogram is comparable to a diagnostic hysteroscopy, especially if it's a three-dimensional sonogram. You can see a lot of details with that. If the saline-infused sonogram demonstrates an abnormality, I will then perform an operative hysteroscopy for treatment. If I have a patient who fails two IVF cycles and has only had normal results on a saline-infused sonogram, I will typically perform a hysteroscopy and sometimes a laparoscopy to make sure there is not anything we are missing. We rarely will fi nd anything because we are so attentive to making sure the uterus is normal prior to IVF, but it will happen occasionally. Dr. Miller: I take a similar approach and will also typically wait until two failed IVF cycles before following up a saline-infused sonogram with hysteroscopy, although it depends in part on the age of the patient and their insurance coverage. In a woman who is older, there is more urgency to accomplish your goal. We are fortunate that Illinois is a state that mandates fertility coverage as part of health insurance, but for patients who do not have that coverage, each IVF cycle can be a significant fi nancial burden. It's therefore vital to perform appropriate diagnostic testing so that you are absolutely sure of the patient's pathology. In those cases, I would likely only wait until one failed cycle or even add hysteroscopy to a saline-infused sonogram upfront. I would also be more likely to use mechanical hysteroscopic tissue removal to biopsy tissue and look for any plasma cells in the sample to rule out a possible occult endometritis.
